首页> 美国卫生研究院文献>SpringerPlus >A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

【2h】

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

机译：纳米粒白蛋白结合紫杉醇联合或不联合米非司酮治疗晚期乳腺癌的随机I期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeGlucocorticoid receptor (GR) overexpression is associated with poor prognosis ER-negative breast cancer. GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we conducted a phase I clinical trial of mifepristone and nab-paclitaxel in advanced breast cancer.

机译：目的糖皮质激素受体（GR）的过度表达与ER阴性乳腺癌的预后不良有关。米非司酮与GR拮抗作用会增加化疗诱导的乳腺癌细胞死亡，因此，我们对米非司酮和nab-紫杉醇进行了晚期乳腺癌的I期临床试验。

著录项

期刊名称 SpringerPlus
作者
Rita Nanda; Erica M. Stringer-Reasor; Poornima Saha; Masha Kocherginsky; Jean Gibson; Bernadette Libao; Philip C. Hoffman; Elias Obeid; Douglas E. Merkel; Galina Khramtsova; Maxwell Skor; Thomas Krausz; Ronald N. Cohen; Mark J. Ratain; Gini F. Fleming; Suzanne D. Conzen;
展开▼
作者单位

展开▼
年(卷),期 -1(5),1
年度 -1
页码 947
总页数 9
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) [J] . Rugo Hope S., Barry William T., Moreno-Aspitia Alvaro, Journal of Clinical Oncology . 2015,第21期

机译：每周一次紫杉醇与绑定纳米白蛋白的Nab-紫杉醇每周一次或与伊沙贝比隆联合贝伐单抗作为局部复发或转移性乳腺癌的一线化疗的随机III期试验：CALGB 40502 / NCCTG N063H（联盟）
2. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) [J] . Morgensztern Daniel, Cobo Manuel, Aix Santiago Ponce, Cancer: A Journal of the American Cancer Society . 2018,第24期

机译：Abound.2L +：随机相2研究纳米粒子白蛋白 - 结合紫杉醇，具有或不含CC-486作为先进的非小细胞肺癌（NSCLC）的二线治疗
3. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer [J] . SeidmanA.D., ConlinA.K., BachA., Clinical breast cancer . 2013,第4期

机译：每周，每2周和每3周进行纳米级白蛋白结合紫杉醇联合贝伐单抗作为转移性乳腺癌的一线化疗的随机II期试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. TBCRC 019: An open label randomized phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC or Abraxane®) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer [O] . Andres Forero-Torres, Katherine E. Varley, Vandana Gupta Abramson, -1

机译：TBCRC 019：一项开放性随机II期临床试验纳米粒白蛋白结合的紫杉醇（nab-PAC或Abraxane®）含或不含抗死亡受体5（DR5）单克隆抗体tigatuzumab在转移性三阴性乳腺癌患者中的应用
7. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer [O] . 2016

机译：纳米粒白蛋白结合紫杉醇联合或不联合米非司酮治疗晚期乳腺癌的随机I期试验

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅